When “Clear” Isn't the Whole Story: Rethinking Unmet Need in Psoriasis

This Q&A examines where unmet need can remain despite advances in psoriasis treatment, including residual symptoms, high-impact disease, comorbidities, and differences between clinical response and the patient’s experience of disease control.

1. With today’s treatments, where does unmet need remain in psoriasis?

Rather than eliminating unmet need, therapeutic advances have raised expectations for psoriasis control. Recent advances in therapeutic targets have significantly altered the treatment landscape, yet high rates of biologic discontinuation and switching indicate that unmet need persists.¹ Clearance carries incremental benefit: greater degrees of skin clearance were associated with more substantial improvements in quality of life and skin symptom burden, and complete skin clearance was associated with a considerably larger proportion of patients achieving symptom resolution compared with almost complete clearance.² Not every patient achieves or maintains complete clearance, and meaningful burden may remain despite a strong clinical response. In one study of 96 biologic-treated patients who had achieved at least 75% improvement in their Psoriasis Area and Severity Index (PASI) score, only 37.5% achieved PASI 100.³

2. When the skin is clear or nearly clear, what else should be considered?

Visible skin response and patient-experienced disease control are closely related but not interchangeable. Most patients who reach clear or nearly clear skin do well, but confirming that the patient's experience aligns with the clinical response is important. Symptoms, psychosocial effects, and quality-of-life concerns are important dimensions of psoriasis burden and may not be fully represented by visible skin assessment alone.^4-6 In one study, even among patients who achieved clear skin, quality of life was significantly worse among those with previous biologic treatment failure.³ Visible clearance remains an important treatment outcome, but confirming that it aligns with the patient's broader experience provides a more complete assessment of disease control.

3. Why can limited skin involvement still represent meaningful disease burden?

Because limited extent does not necessarily mean limited impact. Disease location can have a disproportionate impact relative to overall extent. Although psoriasis in special areas affects a smaller proportion of body surface, the effect on quality of life is significant, and these sites carry important physical and emotional implications including social isolation and work disability.⁷ The scalp, nails, face, genital area, palms, and soles are all locations where modest involvement can produce substantial symptomatic, functional, or psychosocial burden, and these sites are common: prevalence is estimated at 23% to 27% for nails, 49% for the face, and 12% to 16% for palms and soles.⁸ Genital disease illustrates the point: it significantly affects quality of life and sexual health; itch is reported by 82% to 100% of those affected, yet embarrassment and inadequate assessment leave it frequently undiagnosed and untreated.⁸ Contemporary assessment reflects this. The International Psoriasis Council severity classification weighs involvement of high-impact sites and treatment history alongside body surface area.⁹

4. What does a comprehensive assessment of psoriasis control include?

A comprehensive assessment considers objective skin control alongside other dimensions of disease burden and the patient experience.

Skin + Symptoms + Joints/Comorbidities + Daily Life + Patient Goals

Objective skin control matters, as does involvement of high-impact sites. Itch and pain are both worth asking about directly.^4,5 Relevant comorbidities—including psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric disorders—should also be considered and may influence treatment decisions.¹ Quality of life, function, and psychosocial burden provide additional context, as do treatment burden, tolerability, convenience, and patient preferences.^6,10

5. What should treatment success look like in psoriasis today?

Treatment success should be multidimensional without diminishing the importance of objective disease assessment. High levels of skin clearance remain an important goal, and objective assessment remains essential to judging visible disease. Alongside it, a fuller account of control considers residual symptoms, disease at high-impact sites, quality of life and function, relevant comorbid disease (including psoriatic arthritis), the burden of treatment itself, and the patient’s priorities and sense of how well their disease is controlled. No single definition of success fits every patient.

Clinical takeaway: When a patient appears clear or nearly clear, confirm that the clinical response is reflected in the patient’s symptoms, daily life, and perception of disease control.

References

1. Ukkola-Vuoti L, Klåvus A, Toppila I, Hällfors J, Veijalainen L, Mälkönen T. A population-based registry study on psoriasis-associated burden of disease in Finland. Front Med (Lausanne). 2025;12:1605100. doi:10.3389/fmed.2025.1605100
2. Lacour JP, Bewley A, Hammond E, et al. Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL). Dermatol Ther (Heidelb). 2020;10(5):1099-1109. doi:10.1007/s13555-020-00428-1
3. Song WJ, Yoon HS. Impact of residual skin lesions and previous biologic treatment failure on patient-reported outcomes in patients with psoriasis receiving biologic treatment. J Dermatol. 2024;51(6):772-778. doi:10.1111/1346-8138.17249
4. Taliercio VL, Snyder AM, Webber LB, et al. The disruptiveness of itchiness from psoriasis: a qualitative study of the impact of a single symptom on quality of life. J Clin Aesthet Dermatol. 2021;14(6):42-48.
5. Snyder AM, Taliercio VL, Webber LB, et al. The role of pain in the lives of patients with psoriasis: a qualitative study on an inadequately addressed symptom. J Psoriasis Psoriatic Arthritis. 2022;7(1):29-34. doi:10.1177/24755303211066928
6. Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:25-33. doi:10.2147/PTT.S328447
7. Butacu AI, Toma C, Negulet IE, et al. Updates on psoriasis in special areas. J Clin Med. 2024;13(24):7549. doi:10.3390/jcm13247549
8. Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392-398. doi:10.5114/reum.2018.80718
9. Lupulescu AM, Savu AP, Bucur Ş, Şerban ED, Popescu S, Constantin MM. Hard-to-treat areas in psoriasis: an underevaluated part of the disease. Life (Basel). 2025;15(3):425. doi:10.3390/life15030425
10. Esposito M, Giunta A, Gisondi P, et al. Satisfaction and attitudes toward systemic treatments for psoriasis: a cross-sectional study. Dermatol Ther. 2021;34(3):e14949. doi:10.1111/dth.14949